IBD type | Outcome measures | Number of studies | Overall[percentage; 95% CI] |
---|---|---|---|
CD | Remission | ||
2 weeks | 2 | 8/36[22;11–42] | |
6 weeks | 4 | 19/75[25;17–37] | |
12 weeks | 1 | 26/71[37;25–48] | |
14 weeks | 6 | 25/85[28;18–37] | |
22 weeks | 3 | 17/53[32;19–44] | |
24 weeks | 1 | 32/73[44;32–55] | |
30 weeks | 2 | 12/24[52;10–93] | |
1 year | 3 | 43/92[46;36–57] | |
Response | |||
6 weeks | 1 | 5/15[33;9–57] | |
14 weeks | 4 | 20/39[52;37–67] | |
22 weeks | 1 | 9/15[60;35–85] | |
30 weeks | 1 | 6/13[46;19–73] | |
1 year | 1 | 5/10[50;19–81] | |
CS-free clinical remission | |||
6 weeks | 1 | 1/15[7;-6–19] | |
12 weeks | 1 | 24/71[34;23–45] | |
14 weeks | 3 | 5/37[14;3–29] | |
22 weeks | 3 | 12/47[26;11–36] | |
24 weeks | 1 | 30/73[41;30–52] | |
26 weeks | 1 | 5/7[71;38–105] | |
38Â weeks | 1 | 0/6[0;NA] | |
1 year | 1 | 35/78[45;34–56] | |
UC/IBD-U | Remission | ||
2 weeks | 2 | 11/27[41;22–59] | |
6 weeks | 4 | 25/70[36;10–57] | |
12 weeks | 1 | 37/79[47;36–58] | |
14 weeks | 6 | 52/101[48;31–65] | |
22 weeks | 3 | 24/45[53;36–73] | |
24 weeks | 1 | 42/79[53;42–64] | |
30 weeks | 2 | 21/31[68;52–84] | |
1 year | 3 | 50/112[45;35–54] | |
Response | |||
2 weeks | 1 | 1/5[20;–15–55] | |
6 weeks | 1 | 1/4[25;–17–67] | |
14 weeks | 3 | 30/44[69;53–84] | |
22 weeks | 1 | 2/4[50;1–99] | |
30 weeks | 1 | 18/23[78;61–95] | |
1 year | 1 | 15/21[71;52–91] | |
CS-free clinical remission | |||
6Â weeks | 1 | 0/5[0;NA] | |
12 weeks | 1 | 35/79[44;33–55] | |
14 weeks | 3 | 17/44[39;17–51] | |
22 weeks | 3 | 26/45[58;44–73] | |
24 weeks | 1 | 39/79[49;38–60] | |
26 weeks | 1 | 7/9[78;51–105] | |
38 weeks | 1 | 4/5[80;45–115] | |
1 year | 1 | 33/81[41;30–51] |